睡眠時随伴症の非薬物療法 (Hypnosomnia)
睡眠時随伴症に対する非薬物療法の有効性の評価: ランダム化比較試験
The goal of this clinical trial is to compare the efficacy of non-pharmacological treatments (medical hypnosis and standard treatment) in patients with a non-REM parasomnia diagnosis (N=60).
Participants are randomly assigned to one of the two treatments. Treatment consists of 3 sessions. Participants receiving the standard treatment (i.e., sleep hygiene and episode risk reduction) may subsequently receive medical hypnosis.
Participation in the study involves 5 visits in total: 3 treatment visits and 2 study visits to the hospital (CHUV).
- An initial study visit to provide information and collect questionnaires prior to the start of treatment. An initial non-therapeutic hypnosis session will be carried out during electroencephalography (EEG). Estimated duration: 2h.
- A second study visit at the end of treatment, including questionnaires about your sleep and treatment. A shorter non-therapeutic hypnosis session and a second EEG will be performed. Estimated duration: 1h30. This visit may also be followed by an overnight polysomnography, according to patient's choice (if performed, estimated total duration 12 hrs).
This study also involves monitoring patients' sleep for 10 nights before and after treatment: they will fill in a sleep diary and use an infrared camera.
For the validation of the EEG methodology, healthy volunteers (N=50) will complete a unique visit resembling the initial study visit of patients.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Canton of Vaud
-
Lausanne、Canton of Vaud、スイス、1005
- Centre hospitalier universitaire vaudois (CHUV)
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Patients with NREM parasomnia (N=60):
Inclusion Criteria:
- Non-REM parasomnias diagnosis according to the international classification disease of sleep disorders
- Willling and able to give informed consent
- Reporting at least one parasomniac episode per month
- Reporting at least one parasomniac episode the month prior
Exclusion Criteria:
- Refusal to use the home video recording device
- Current or planned intake (during the next 2 months) of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines)
- A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia)
- A comorbid sleep disorder (e.g., apnea-hypopnea index (AHI) >= 20/hour, REM sleep behaviour disorder, restless legs syndrome with symptoms more than 2 days/week)
- A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder)
Healthy volunteers (N=50):
Inclusion Criteria:
- Adult (≥ 18 yo) willing and able to give informed consent.
Exclusion criteria:
- Presence of NREM parasomnias diagnosis, or any other concomitant sleep disorder;
- Current intake of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines);
- A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia);
- A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder);
- Current history of psychiatric or neurological disorders (e.g., migraines).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Medical hypnosis (HYP) (N=30)
3 medical hypnosis interventions |
Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation) |
|
アクティブコンパレータ:Standard Of Care (SOC) (N=30)
3 standard of care quality and sleep safety interventions |
Sleep hygiene and safety education session |
|
介入なし:Healthy volunteers (N=50)
Unique EEG visit resembling the initial study visit of patients with NREM parasomnias |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change, from pre-treatment, of mean number of parasomniac episodes at 9 weeks
時間枠:Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment
|
Parasomniac episodes scored on infrared home video recording |
Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of parasomniac episodes
時間枠:Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment
|
Using home video recording |
Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment
|
|
Rate of confusional arousals, sleepwalking and sleep terrors episodes
時間枠:Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment
|
Categorization of parasomniac episodes' complexity (confusional arousals, sleepwalking, sleep terrors) using home video recording |
Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment
|
|
Incidence of emotions related to parasomniac episodes
時間枠:Through study duration, an average of 9 weeks
|
Emotional impact of parasomniac episodes using questionnaires (e.g., What emotions did you feel during these episodes?; Do you have negative emotions related to your parasomnias?) |
Through study duration, an average of 9 weeks
|
|
Quality of life score
時間枠:At Day 0, Week 11 and Week 18
|
Using a standardized questionnaire: World Health Organization Quality Of Life-BREF (WHOQOL-BREF). Score ranging from 0 to 100, higher score denoting greater perceived quality of life. |
At Day 0, Week 11 and Week 18
|
|
Anxiety and depression scores
時間枠:At Day 0 and Week 11
|
Using a standardized questionnaire: Hospital Anxiety and Depression Scale (HADS). Subscale score ranging from 3 to 21, score >8 denotes anxiety or depression. |
At Day 0 and Week 11
|
|
Traumatic events score
時間枠:At Day 0
|
Using a standardized questionnaire: Life Event Checklist for DSM-5 (LEC-5). It does not yield a total score or a composite score. |
At Day 0
|
|
Fatigue score
時間枠:At Week 2, Week 11 and Week 18
|
Using a standardized questionnaire: Pichot's fatigue scale. Score ranging from 0 to 32, score >22 denotes excessive fatigue. |
At Week 2, Week 11 and Week 18
|
|
Sleepiness score
時間枠:At Week 2, Week 11 and Week 18
|
Using a standardized questionnaire: Epworth Sleepiness Scale (ESS). Score ranging from 0 to 24, higher score denoting higher daytime sleepiness. |
At Week 2, Week 11 and Week 18
|
|
Sleep quality score
時間枠:At Week 2, Week 11 and Week 18
|
Using a standardized questionnaire: Pittsburgh Sleep Quality Index (PSQI). Score ranging from 0 to 21, higher score denoting greater acute sleep disturbances. |
At Week 2, Week 11 and Week 18
|
|
Severity of arousal disorders score
時間枠:At Week 2, Week 11 and Week 18
|
Using a standardized questionnaire: Paris Arousal Disorders Severity Scale (PADSS). Score ranging from 0 to 50, higher score denoting more severed disorders. |
At Week 2, Week 11 and Week 18
|
|
Circadian typology score
時間枠:At Week 2, Week 11 and Week 18
|
Using a standardized questionnaire: Horne & Östberg questionnaire. Score ranging from 16 to 86, higher score denoting morningness and lower score eveningness. |
At Week 2, Week 11 and Week 18
|
|
Changes in sleep architecture
時間枠:At Day 0 and Week 11
|
Using power spectral sleep EEG analysis including delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), sigma (12-16 Hz), and beta (18-30 Hz) frequency bands with Titanium, Embla®, NOX-A1®. |
At Day 0 and Week 11
|
|
Sleep eye movements
時間枠:At Week 11 (optional)
|
Using power spectral sleep EOG analysis (left and right) with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Sleep muscles activity
時間枠:At Week 11 (optional)
|
Using power spectral sleep EMG analysis (chin and anterior tibialis muscle) with Titanium, Embla®, NOX-A1® |
At Week 11 (optional)
|
|
Sleep cardiac activity
時間枠:At Week 11 (optional)
|
Using power spectral sleep ECG analysis (P wave, QRS complex, QT interval, PR interval...) with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Sleep oxygen saturation
時間枠:At Week 11 (optional)
|
Using sleep oxygen saturation measures with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Sleep airflow
時間枠:At Week 11 (optional)
|
Using sleep airflow measures with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Sleep respiratory efforts
時間枠:At Week 11 (optional)
|
Using abdominal and thoracic respiratory efforts measures with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Snoring
時間枠:At Week 11 (optional)
|
Using snoring measures with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Changes in imagery processes
時間枠:At Day 0 and Week 11 for patients.
|
Using patients' EEG measures (N=60) collected with a 124-channel waveguardTMoriginal EEG cap and during 3-minute pleasant imagery suggestion audio recordings. |
At Day 0 and Week 11 for patients.
|
|
Validation of the EEG methodology for the imagery processes recordings
時間枠:At Day 0
|
Using healthy volunteers' EEG measures (N=50) collected with a 124-channel waveguardTMoriginal EEG and during 5-minute pleasant imagery suggestion audio recordings. |
At Day 0
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Chantal Berna Renella, Prof、CHUV
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CER-VD 2023-01007
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。